ALK and non-small cell lung carcinoma: ,23 Camrelizumab, an anti–PD-1 monoclonal antibody, as monotherapy, has exhibited marked efficacy across multiple solid tumors24, 25, 26, 27 and has recently been approved in combination with chemotherapy as a first-line treatment for advanced nonsquamous NSCLC without EGFR or ALK alterations in People's Republic of China.28